糖尿病性ケトアシドーシスの補助療法としてのチアミン
調査の概要
詳細な説明
チアミン (ビタミン B1) は水溶性ビタミンで、好気性グルコース代謝で重要な役割を果たします。 チアミンは、好気性代謝のためにクレブス回路に入るために活性化されなければならない酵素であるピルビン酸デヒドロゲナーゼ (PDH) の補因子です。 チアミン欠乏状態では PDH 活性が低下し、ピルビン酸代謝が嫌気性経路に移行します。 これにより、乳酸産生とアシドーシスが増加します。 糖尿病では、チアミン欠乏症を伴う尿中のチアミン損失は珍しくありません。 研究者らの予備研究では、DKA 患者の 39% にチアミン欠乏症が発生し、チアミン濃度が乳酸およびアシドーシスと反比例の関係にあることがわかっています。 研究者は、チアミンの静脈内投与で DKA 患者を治療すると、アシドーシスの迅速な解決と好気性代謝の改善につながるという仮説を立てています。 研究者の二次仮説は、チアミン治療は ICU と病院での滞在を短縮し、病院のリソースの利用を減らすというものです。
このランダム化二重盲検プラセボ対照試験では、研究に登録された DKA で入院した患者は、静脈内チアミン (0.9% 生理食塩水中 200mg) を 1 日 2 回 2 日間投与するか、同量の同じスケジュールで 0.9% 生理食塩水。 研究者の主な結果は、線形混合効果モデルを使用して、0、6、12、18、24 時間での測定による、登録後 24 時間にわたる重炭酸塩の変化です。 次に、患者はタイプ I およびタイプ II DM によって層別化されます。 さらに、チアミン欠乏被験者の事前に計画されたサブ分析が実行されます。
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Beth Israel Deaconess Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
説明
包含基準:
- 重炭酸塩 ≤15 mEq/L
- 陰イオンギャップ > 12 mEq/L
- -血液pH≤7.24(臨床チームによってすでに取得されている場合)
- 尿中ケトン(定性的)または血清ケトン(β-ヒドロキシ酪酸) > 3 mmol/L
- プレゼンテーションから6時間以内の登録
除外基準:
- 現在のチアミン補充量は 1 日あたり 6 ミリグラム以上 (つまり、マルチビタミン以上)
- 発作、一酸化炭素中毒、シアン化物中毒、心停止、肝機能障害(特に既知の肝硬変として定義される)を含む重度のアシドーシスの競合する原因
- チアミンに対する既知のアレルギー
- -臨床チームによって判断されたチアミン投与の競合する適応症(例:アルコール依存症)
- 研究対象集団(妊婦、囚人、知的障害者)
- -以前に同じ研究に登録された患者
- Do Not Resuscitate/Do Not Intubate (DNR/DNI) または Comfort Measures Only (CMO) のコードステータス
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:チアミン
50mL 0.9% 生理食塩水中の 200mg IV チアミンを 1 日 2 回、2 日間
|
チアミン 200mg IV、12 時間ごと、2 日間
他の名前:
|
|
プラセボコンパレーター:プラセボ
100mL 0.9% 生理食塩水を 1 日 2 回、2 日間
|
50mL 0.9%生理食塩水
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Plasma Bicarbonate Levels
時間枠:6, 12, 18, and 24 hours after enrollment
|
Primary outcome of plasma bicarbonate levels over 24 hours (6, 12, 18, 24 hours) following enrollment
|
6, 12, 18, and 24 hours after enrollment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Lactate
時間枠:6, 12, 18, and 24 hours after enrollment
|
Secondary outcome of lactate over 24 hours (6, 12, 18, 24 hours) following enrollment
|
6, 12, 18, and 24 hours after enrollment
|
|
Anion Gap
時間枠:6, 12, 18, and 24 hours after enrollment
|
Secondary outcome of anion gap over 24 hours (6, 12, 18, 24 hours) following enrollment
|
6, 12, 18, and 24 hours after enrollment
|
|
ICU Length of Stay
時間枠:45 days
|
ICU length of stay reflects the number of ICU admission days.
|
45 days
|
|
Hospital Length of Stay
時間枠:45 days
|
Hospital length of stay reflects how long it takes a diabetic ketoacidosis patient to recover to the point where he/she can be released from the hospital.
|
45 days
|
|
Duration of Insulin Therapy
時間枠:First 7 days after enrollment
|
The duration of insulin therapy is calculated by examining the hospital clinical information systems for all records of IV insulin infusion beginning at the time of enrollment.
The start and the stop time-stamps of medication infusion are used to calculate a duration of infusion.
|
First 7 days after enrollment
|
|
SOFA Score (Sequential Organ Failure Assessement Score)
時間枠:24 hours
|
The SOFA score is a validated measure of organ dysfunction commonly used in critically ill patients, particularly those with sepsis.
It evaluates the function of six organ systems-respiratory, cardiovascular, neurologic, hepatic, renal, and coagulation-based on routinely collected clinical and laboratory data.
Each organ system is assigned a score from 0 (normal function) to 4 (most severe dysfunction), resulting in a total score ranging from 0 to 24.
Higher SOFA scores indicate greater severity of organ failure and a higher risk of adverse outcomes.
SOFA score in this study uses a modification in which the arterial oxygen saturation/fraction of inspired oxygen (SaO2 /FiO2) ratio is substituted for the partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2 /FiO2 ratio).
|
24 hours
|
|
Oxygen Consumption by Circulating Mononuclear Cells
時間枠:24 hours
|
Oxygen consumption rate of circulating peripheral blood mononuclear cells measured using Seahorse.
Basal respiration represents oxygen consumption under baseline conditions.
ATP-linked respiration represents oxygen consumption coupled to ATP production, while proton leak represents oxygen consumption not linked to ATP synthesis.
Maximal respiration represents the maximal capacity of the electron transport chain after uncoupling.
Spare respiratory capacity represents the difference between maximal and basal respiration and indicates the ability to respond to increased energy demand.
Non-mitochondrial respiration represents oxygen consumption independent of mitochondrial activity.
|
24 hours
|
|
Pyruvate Dehydrogenase Activity
時間枠:24 hours and 72 hours (or at discharge if hostpial length of stay was less than 72 hours)
|
Secondary outcome of change in PDH specific activity over 72 hours or at discharge if patient's hospital length of stay was less than 72 hours.
PDH activity and total PDH protein quantity were measured in isolated peripheral blood mononuclear cells (PBMCs) following selective disruption of the mitochondrial membrane, using a previously validated immunocapture and microplate-based enzymatic assay protocol.
PDH-specific activity was calculated as the ratio of measured PDH enzymatic activity to the natural logarithm of PDH protein quantity (PDH activity / ln[PDH quantity]), providing a normalized metric that reflects the functional efficiency of the enzyme independent of its expression level.
Higher values suggest higher enzymatic efficiency.
|
24 hours and 72 hours (or at discharge if hostpial length of stay was less than 72 hours)
|
|
Neurocognitive: Hopkins Verbal Learning Test - Total Recall
時間枠:At hospital discharge, median of 4 days
|
The Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall score is a measure of verbal learning and immediate memory.
Participants are read a list of 12 words (from three semantic categories) and asked to recall as many words as possible across three consecutive learning trials.
The Total Recall score is calculated as the sum of correctly recalled words across the three trials, yielding a possible range of 0 to 36, with higher scores indicating better verbal learning and memory performance.
This score reflects both initial acquisition and short-term retention of verbal information and is commonly used to assess cognitive function in clinical research.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Hopkins Verbal Learning Test - Delayed Recall
時間枠:At hospital discharge, median of 4 days
|
The Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall score assesses retention of verbal information after a delay.
Following completion of the three learning trials, participants are asked to recall the previously presented word list after a delay period (typically 20-25 minutes) without re-exposure to the words.
The Delayed Recall score is calculated as the number of correctly recalled words, with a possible range of 0 to 12, where higher scores indicate better memory retention.
This measure reflects the ability to consolidate and retrieve learned information over time and is commonly used to evaluate memory function in clinical and research settings.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Hopkins Verbal Learning Test - Retention
時間枠:At hospital discharge, median of 4 days
|
The Hopkins Verbal Learning Test-Revised (HVLT-R) Retention (%) score reflects the proportion of learned information that is retained over a delay.
It is calculated as the ratio of the Delayed Recall score to the highest number of words recalled on any of the three immediate recall trials, multiplied by 100, yielding a percentage value.
Scores typically range from 0% to 100%, with higher values indicating better retention of previously learned material.
This measure provides an index of memory retention independent of initial learning performance.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Hopkins Verbal Learning Test - Recognition Discrimination Index
時間枠:At hospital discharge, median of 4 days
|
The Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index assesses recognition memory by evaluating the ability to distinguish previously learned words from novel distractors.
During the recognition phase, participants are presented with a list of target words and distractor words and asked to identify those that were previously learned.
The Recognition Discrimination Index is calculated as the number of true positives (correctly identified target words) minus the number of false positives (incorrectly identified distractor words), yielding a score typically ranging from -12 to 12. Higher scores indicate better recognition accuracy and discrimination ability, reflecting the integrity of memory retrieval processes.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Brief Visuospatial Memory Test
時間枠:At hospital discharge, median of 4 days
|
The Brief Visuospatial Memory Test (BVMT) assesses visuospatial learning and memory.
Participants are shown six geometric designs for a brief period and asked to reproduce them from memory across three learning trials.
Performance is scored based on the accuracy and placement of each design, with a total recall score ranging from 0 to 36, where higher scores indicate better visuospatial memory.
A delayed recall trial is administered after a delay to assess retention of visual information.
This measure evaluates the ability to encode, store, and retrieve visuospatial material.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Trail Making Test - Test Part A
時間枠:At hospital discharge, median of 4 days
|
The Trail Making Test Part A (TMT-A) assesses visual attention, processing speed, and psychomotor function.
Participants are instructed to connect numbered circles in sequential order as quickly as possible.
The primary outcome is the time to completion, measured in seconds, with lower times indicating better performance.
There is no fixed maximum score, although testing is typically discontinued at a predefined time limit (commonly 300 seconds).
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Trail Making Test - Test Part B
時間枠:At hospital discharge, median of 4 days
|
The Trail Making Test Part B (TMT-B) assesses executive function, including cognitive flexibility and set-shifting, in addition to processing speed.
Participants are required to alternate between numbers and letters in sequence (e.g., 1-A-2-B) as quickly as possible.
The primary outcome is the time to completion, measured in seconds, with lower times indicating better performance.
As with TMT-A, there is no fixed maximum score, and testing is typically discontinued at a predefined time limit (commonly 300 seconds).
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: WAIS-IV Digit Span
時間枠:At hospital discharge, median of 4 days
|
The Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Digit Span subtest assesses attention, working memory, and concentration.
Participants are asked to repeat sequences of numbers in forward order (Digit Span Forward), reverse order (Digit Span Backward), and ascending order (Digit Span Sequencing).
Scores are based on the total number of correctly recalled sequences, with higher scores indicating better attention and working memory capacity.
The total score ranges from 0 to 48.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Test of Verbal Fluency and Animal Naming
時間枠:At hospital discharge, median of 4 days
|
The Animal Naming test is a measure of semantic verbal fluency and executive function.
Participants are asked to name as many animals as possible within a fixed time period.
The score is the total number of unique, correct animal names generated, with higher scores indicating better semantic memory retrieval and executive functioning.
Scores range from 0 with no fixed upper limit.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Test of Premorbid Functioning
時間枠:At hospital discharge, median of 4 days
|
The Test of Premorbid Functioning (TOPF) estimates an individual's baseline cognitive ability prior to illness or injury.
Participants are asked to read aloud a list of irregularly spelled words, and performance is scored based on correct pronunciation.
Scores are used to estimate premorbid intellectual functioning.
Scores range from 0 to 70, with higher scores indicating higher estimated premorbid functioning.
This measure helps contextualize current cognitive performance relative to expected baseline levels.
|
At hospital discharge, median of 4 days
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
C-peptide Levels
時間枠:0, 24 hours, and 72 hours (or at discharge if hospital length of stay was less than 72 hours)
|
C-peptide levels measured at time of study drug administration, 24 hours, and at 72 hours (or at discharge if hospital length of stay was less than 72 hours).
|
0, 24 hours, and 72 hours (or at discharge if hospital length of stay was less than 72 hours)
|
協力者と研究者
捜査官
- 主任研究者:Michael Donnino, MD、Beth Israel Deaconess Medical Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2018P000475
- 1R01DK112886-01A1 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。